NEU 1.52% $12.94 neuren pharmaceuticals limited

Share Price, page-11809

  1. 1,189 Posts.
    lightbulb Created with Sketch. 155
    Whilst I agree with the sentiment, I think the reason why so many are nervous (and even potentially against going alone) is the fear of not see the SP appreciate during P3 and PRIOR to results. If phase 3 is successful, then any significant rerate may only be after FDA approval - which then adds even more time to an already long wait!

    Someone previously shared detailed SP movements during phase 3 trials and from memory, the share price almost always declined throughout the process in the lead up to results

    Although in saying that, perhaps it's different this time given the comparison and success of Daybue to peg 2591 to - here's hoping!!

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.